STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Stromal antigen 2 (STAG2) is a tumor suppressor frequently mutated or lost in various cancers, including osteosarcoma (OS).
• The precise mechanisms by which STAG2 alterations contribute to tumorigenesis remain largely undefined.

Purpose of the Study:

• To investigate the functional consequences of STAG2 loss in osteosarcoma (OS) tumorigenesis.
• To elucidate the role of STAG2 in cell proliferation, chemo-resistance, metastasis, and immune evasion in OS.

Main Methods:

• Analysis of STAG2 mutation distribution across cancers using the COSMIC database.
• Generation of STAG2-deficient OS cell lines (U2OS) to mimic common mutations.
• Assessment of cell proliferation, chemo-resistance, apoptosis, and cell cycle using CCK-8 and flow cytometry assays.
• Transcriptome profiling via RNA sequencing (RNA-Seq) to identify gene expression changes.

Main Results:

• STAG2-deficient OS cells showed decreased proliferation but increased metastasis and invasion.
• Loss of STAG2 conferred enhanced tolerance to chemotherapeutic agents, including cisplatin.
• Upregulation of PD-L1, a key molecule in tumor immune evasion, was observed in STAG2-deficient cells.
• RNA-seq analysis revealed significant alterations in immune-related gene expression.

Conclusions:

• STAG2 loss in OS promotes tumorigenesis by enhancing cell survival and chemo-resistance.
• Deletion of STAG2 appears to facilitate tumor progression through increased immune evasion capacity.
• Targeting STAG2-related pathways may offer novel therapeutic strategies for osteosarcoma.